Showing 2881-2890 of 5646 results for "".
- Trabeculectomy Outcomes Different for Individuals of African vs European Descenthttps://modernod.com/news/trabeculectomy-outcomes-different-for-patients-of-african-vs-european-descent/2479955/Individuals of African descent (AD) and those of European descent (ED) tend to have different outcomes after trabeculectomy with mitomycin C, according to a report in JAMA Ophthalmology. “African descent was associate
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- Wills Eye Sponsors First Early Feasibility Study of a New Implantable Device for Blind Retinitis Pigmentosa Patientshttps://modernod.com/news/wills-eye-sponsors-first-us-early-feasibility-study-of-a-new-implantable-device-for-blind-retinitis-pigmentosa-patients/2479960/Wills Eye Hospital has been given FDA approval to begin an early feasibility study (EFS) to implant the RETINA IMPLANT Alpha AMS sub-retinal device in patients blind due to retinitis pigmentosa (RP). The Alpha AMS is manufactured by Retina Implant AG, Reutlingen,
- AAO Launches New Scientific Journal Dedicated to Glaucoma Researchhttps://modernod.com/news/aao-launches-new-scientific-journal-dedicated-to-glaucoma-research/2479972/The American Academy of Ophthalmology announced the launch of Ophthalmology Glaucoma, a scientific journal focused exclusively on glaucoma. As development of next-generation glaucoma devices and drugs surges, Ophthalmology Glaucoma offers researchers an expanded opportunity to pu
- Topical Presbyopia Treatment Advances in Clinical Developmenthttps://modernod.com/news/presbyopia-therapies-announces-primary-safety-and-efficacy-resutls-in-phase-2b-study-of-topical-presbyopia-treatment/2479978/Presbyopia Therapies announced that the primary efficacy and safety endpoints have been met in a phase 2b study of its PRX ophthalmic solution. PRX demonstrated a 3 line or greater improvement in monocular distance corrected near acuity in patients between the ages of 48 and 64, with this improve
- OCT Angiography Predicts Exudation in Macular Degenerationhttps://modernod.com/news/oct-angiography-predicts-exudation-in-macular-degeneration/2479981/Optical coherence tomography (OCT) angiography can help predict which eyes affected by age-related macular degeneration are most likely to develop exudation, research shows, according to a report in Medscape. The new technology can
- State Strips Ex-USC Medical School Dean of License, Citing ‘An Appalling Lack of Judgment’https://modernod.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/The California state agency that regulates physicians ordered USC’s former medical school dean stripped of his license to practice medicine, citing “an appalling lack of judgment” in his use of drugs an
- U.S. Court Rejects Allergan Bid to Shield Patents Through Tribe Dealhttps://modernod.com/news/u-s-court-rejects-allergan-bid-to-shield-patents-through-tribe-deal/2480000/A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan to shield patents from review by an administrative court by transferring them to a Native American tribe, according to a
- Alcon Introduces Ngenuity 3D Visualization System with Datafusion Vitreoretinal Surgery Devicehttps://modernod.com/news/alcon-introduces-ngenuity-3d-visualization-system-with-datafusion-vitreoretinal-surgery-device/2480001/Alcon launched the new Ngenuity 3D Visualization System with Datafusion at the 2018 American Society of Retina Specialists (ASRS) annual meeting. With the addition of the Datafusion software, Ngenuity now also offers integration with the Constellation Vision System for vitreoretinal surgery. The
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T